Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells.
Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells.
复制标题
移植前接受输血的 DLA 相同同窝犬的骨髓排斥：所涉及的抗原在白细胞和皮肤上皮细胞上表达，但在血小板和红细胞上不表达。
作者：
R. Storb;Weiden Pl;H. Deeg;Graham Tc;K. Atkinson;S. Slichter;E. Thomas
先前的研究表明，在接受1200r和来自dla相同窝友的造血移植的狗中，骨髓移植排斥通常不会在受体未输血时发生（59只中有58只实现了持续移植），但在第10天输一次骨髓供者的血液后（18只中有13只被拒绝），甚至在多次输随机血液后（11只中有3只被拒绝）也会发生。本研究通过确定在移植前24、17和10天给予来自骨髓供者的不同细胞后，dla相同的同窝骨髓移植的排斥发生率，扩展了最初的观察结果。使用该方案，建立了以下结果和结论。(1)输注全血的19只狗均有排斥反应。三次输血后100%的排斥反应发生率表明，DLA外不止一个次要组织相容性系统参与了输血诱导的致敏和随后的骨髓移植排斥反应。(2)皮下注射培养的皮肤上皮细胞的6只狗对随后的骨髓移植产生排斥反应。因此，介导排斥反应的抗原不仅限于造血细胞，而且还在至少一种其他组织中表达。(3)输入浓缩血小板（“无”白细胞和红细胞）的15只狗中有7只排斥骨髓移植，8只持续移植。(4)输注红细胞（不含白细胞和血小板）的14只狗中有5只排斥骨髓移植，9只持续移植。这表明只有一些（也许没有）负责排斥反应的非dla抗原存在于血小板和红细胞上。为了明确地回答这个问题，目前的血细胞分离技术必须进一步改进，为输血研究提供纯红细胞和血小板。淋巴细胞毒性抗体测定。混合白细胞培养反应性。供体血小板在受体体内的存活并不能预测后续骨髓移植的命运。这些在dla相同的犬骨髓移植受体中的发现对于规划人类骨髓移植候选人的血小板和红细胞支持具有潜在的实际意义。
Previous studies in dogs given 1 200 R and a hemopoietic graft from DLA-identical littermates have shown that marrow graft rejection generally does not occur when the recipient is untransfused (58 of 59 achieved sustained engraftment) but is seen after a single transfusion of blood from the marrow donor on day -10 (13 of 18 rejected) and even after multiple transfusions of random blood (3 of 1 1 rejected). This study extends those initial observations by determining the incidence of rejection of DLA-identical littermate marrow grafts following administration of different cells from the marrow donor on days 24, 1 7, and 10 prior to transplantation. Using this protocol, the following results and conclusions were established. (1 ) All 1 9 dogs given transfusions of whole blood rejected their grafts. This 1 00% incidence of rejection after three transfusions mdicates that more than one minor histocompatibility system outside of DLA is involved in transfusion-induced sensitization and subsequent marrow graft rejection. (2) Six dogs given subcutaneous injections of cultured skin epithelial cells rejected their subsequent marrow grafts. Hence, antigens mediating rejection are not restricted to hemopoietic cells but are also expressed on at least one other tissue. (3) Seven of 15 dogs given transfusions of platelet concentrates (“free” of white and red blood cells) rejected the marrow graft, while 8 showed sustained engraftment. (4) Five of 14 dogs given transfusions of red blood cells (free of white blood cells and platelets) rejected the marrow graft, while 9 had sustained engraftment. This suggests that only some (and perhaps none) of the non-DLA antigens responsible for rejection reside on platelets and red blood cells. To definitively answer this question, the current blood cell separation techniques must be improved further to provide pure red blood cells and platelets for transfusion studies. Assays of lymphocytotoxic antibodies. mixed leukocyte culture reactivity. and survival of donor platelets in the recipient did not predict the fate of the subsequent marrow graft. These findings in DLA-identical canine marrow graft recipients are of potential practical importance for planning platelet and red blood cell support of human marrow graft candidates.